Cigna to Sell Medicare Businesses to HCSC for $3.7 Billion

News
Article

Once the transaction is complete in the first quarter of 2025, Evernorth Health Services will continue to provide pharmacy benefit services to the Medicare businesses.

The Cigna Group has agreed to sell its Medicare Advantage, Cigna Supplemental Benefits and Medicare Part D business, as well as CareAllies, its valued-based care company, to Health Care Service Corporation (HCSC) for about $3.7 billion. As part of the agreement, Evernorth Health Services, a subsidiary of The Cigna Group, will continue to provide pharmacy benefit services to the Medicare businesses. The transaction is expected to close in the first quarter of 2025.

David M. Cordani

David M. Cordani

“While we continue to believe the overall Medicare space is an attractive segment of the healthcare market, our Medicare businesses require sustained investment, focus, and dedicated resources disproportionate to their size within The Cigna Group's portfolio,” David M. Cordani, chairman and CEO of The Cigna Group, said in a press release.

Cigna plans to use most of the proceeds to repurchase company shares.

Maurice Smith, HCSC’s CEO, president and vice chair said in a press release the acquisition supplements their growth strategy in the Medicare marketplace.

Cigna is expected to release its fourth quarter 2023 earnings on Friday, Feb. 2, 2024, and host an investor day in New York City on March 7, 2024.

Related Videos
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Video 5 - "Obstacles in Adapting Diabetes Technology to Individual Needs" - 1 KOL is featured
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Video 4 - "The Impact of Continuous Glucose Monitors & Digital Solutions on Diabetes Care"
Video 3 - "The Pivotal Role of Patient Engagement and Education in Achieving Optimal Diabetes Outcomes"
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Related Content
© 2024 MJH Life Sciences

All rights reserved.